NCT02067767View on ClinicalTrials.gov

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
HIV-1 Infection
Interventions
DRUG

Abacavir/Lamivudine/Dolutegravir

"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."

Trial Locations (2)

Unknown

La Roche-sur-Yon Hospital, La Roche-sur-Yon

Nantes University Hospital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT02067767 - Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) | Biotech Hunter | Biotech Hunter